Open-label Randomized Controlled Trial for the Effects of Continuous Ethinylestradiol/Levonorgestrel (30/150 μg/Day) Compared With Vitamin E (400 IU/Day) in the Treatment of Menstrually-related Migraine and Migraine During Perimenopause
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Vitamin E
- Indications Menstrual migraine
- Focus Therapeutic Use
- Acronyms WHAT!-RCT; WHATT
Most Recent Events
- 15 Feb 2024 Trial design, published in the Trials
- 07 Dec 2023 Planned End Date changed from 1 Apr 2023 to 1 Dec 2024.
- 07 Dec 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Dec 2024.